UCB (EBR:UCB) UCB Media Room: Acquisition and disposal of own shares
Directive transparence : information réglementée Communiqué sur comptes, résultats, chiffres d’affaires
01/07/2022 20:03
https://mb.cision.com/Public/18595/3595518/9fd13642d9fbf8ad_800x800ar.png
** Acquisition and disposal of own shares
------------------------------------------------------------
Brussels (Belgium), 1 July 2022 =E2=80=93 20:00 (CEST) =E2=80=93 Regulated =
information=C2=A0
Acquisition of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB=
=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose=
s certain information in relation to its Share Repurchase Program 2022.=C2=
=A0
Under this program, UCB has requested a financial intermediary to repurchas=
e up to 500 000 UCB shares on its behalf under the terms of a discretionary=
mandate agreement with initial validity until 31 August 2022, effective as=
from 28 June 2022, to cover current and future obligations under UCB's Lon=
g Term Incentive Plans for its personnel.
In the framework of this Share Repurchase Program 2022, UCB repurchased 103=
000 UCB shares on Euronext Brussels in the period from 28 June 2022 up to =
and including 30 June 2022, as follows:=C2=A0
https://mb.cision.com/Public/18595/3595518/b1cadef97abcd8a8_800x800ar.png
For consistency reasons, UCB confirms that during the same period, it has n=
ot disposed of any UCB shares within the framework of the Long-Term Incenti=
ve Program of the UCB Group.
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://www.ucb.com/stories-media/Press-Releases) .
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte=C2=A0
T +32 2 559 94 14
antje.witte@ucb.com
Corporate Communications
Laurent Schots=C2=A0
T+32 2 559 92 64
laurent.schots@ucb.com =C2=A0=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 600 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.8 bi=
llion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news
=C2=A0
GenericFile
220701 - Rachat et ali=C3=A9nation d actions propres FR final (https://mb.c=
ision.com/Public/18595/3595518/93d9628d8443b199.pdf) GenericFile
220701 - Verwerving en vervreemding van eigen aandelen NL final (https://mb=
.cision.com/Public/18595/3595518/8a9c1d2b38971030.pdf) GenericFile
220701 - Acquisition and disposal of own shares ENG final (https://mb.cisio=
n.com/Public/18595/3595518/ae980f19558e2bdf.pdf) Image
Chart 1 July 1 2022 (https://mb.cision.com/Public/18595/3595518/b1cadef97ab=
cd8a8_org.png)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x109961x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01